A carregar...
Combination of Human Fas (CD95/Apo-1) Ligand with Adriamycin Significantly Enhances the Efficacy of Antitumor Response
The prognosis of hepatocellular carcinoma (HCC) is poor, even with the combined treatment of curative resection and adjuvant chemoradiotherapy. To solve this problem, many biologic therapies have been investigated. Fas ligand (FasL, CD95L) is mainly expressed in activated T lymphocytes and natural k...
Na minha lista:
Main Authors: | , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Nature Publishing Group
2009
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4003059/ https://ncbi.nlm.nih.gov/pubmed/19567199 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cmi.2009.23 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|